🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million instances each year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Authorization

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Clinical Trial Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The research included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Medical professionals treating patients have voiced positive views. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the infection for patients and to halt the transmission of extremely resistant gonorrhoea around the world.